Boehringer receives FDA Breakthrough Therapy designation and initiates two phase III trials in MASH…
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a dual glucagon/GLP-1 receptor…
Read More...
Read More...
